Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Neurology Drugs in Phase I/II Clinical Development in ISRAEL

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Kadimastem

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BE PHARMA 2020

              Participation Not Confirmed

              Update your events

              Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS

              Contact the Supplier

              Lead Product(s): Human astrocytes

              Therapeutic Area: Neurology Product Name: AstroRx

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 03, 2020

              Details:

              Kadimastem's lead product, AstroRx®, showed a positive efficacy signal and a good safety profile in Cohort B of the Company’s Phase 1/2a clinical trial in ALS.

              Kadimastem

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BE PHARMA 2020

              Participation Not Confirmed

              Update your events

              Kadimastem reports positive ALS cell therapy results

              Contact the Supplier

              Lead Product(s): AstroRx

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 02, 2020

              Details:

              A statistically significant decline in disease progression was observed during the first 3- 4 months post-treatment period, indicating a clinical benefit of the AstroRx® cell product.

              PharmaCompass__DigitalAd